Explore more publications!

Anguilla Business Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Anguilla Business Daily.

Press releases published on November 5, 2025

SiTime Reports Third Quarter 2025 Financial Results
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Coherent Corp. Reports First Quarter Fiscal 2026 Results
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Latham Group, Inc. to Participate at the Upcoming Baird 2025 Global Industrial Conference
Sprout Social Announces Third Quarter 2025 Financial Results
The Scotts Miracle-Gro Company Announces Quarterly Dividend Payment
Veeco Reports Third Quarter 2025 Financial Results
Surrozen to Present at Upcoming Healthcare Investor Conference
Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
Generation Bio Announces Third Quarter 2025 Financial Results
Core Molding Technologies to Present and Host 1x1 Meetings at the 17th Annual Southwest IDEAS Investor Conference on November 19, 2025
CVRx Reports Third Quarter 2025 Financial and Operating Results
Interparfums, Inc. Reports 2025 Third Quarter Results
AMSC Reports Second Quarter Fiscal Year 2025 Financial Results and Business Outlook
Lightbridge Provides Business Update and Announces Third Quarter 2025 Financial Results
ARRAY Technologies, Inc. Reports Financial Results for the Third Quarter 2025
Lantronix Reports Fiscal First Quarter 2026 Financial Results
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Galata Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing November 10, 2025

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions